Clinical Trial Update: SCH708980 With and Without AmBisome for Visceral Leishmaniasis [Phase 1, Phase 2]

View source ↗

Summary

The NIAID-sponsored Phase 1/2 trial of SCH708980 for visceral leishmaniasis, with and without AmBisome, has been withdrawn.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Visceral Leishmaniasis

Drugs mentioned

• AMBISOME (AMPHOTERICIN B)
• SCH708980

Snippet

Sponsor: National Institute of Allergy and Infectious Diseases (NIAID) | Conditions: Leishmaniasis, Effects of Immunotherapy | Phase 1, Phase 2 | Status: WITHDRAWN